Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net loss	$ (56,528)	$ (179,817)	$ (229,378)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	833	1,607	1,832
Stock-based compensation expense	20,619	28,518	42,553
In process research and development expenses	0	10,000	65
Amortization of operating lease right-of-use assets	3,318	2,778	2,597
Amortization of long-term debt discount and issuance costs	1,086	1,321	1,163
Amortization of premium on investments, net of accretion of discounts	(13,062)	(9,450)	(1,405)
Loss on disposal of property and equipment	806	726	0
Changes in operating assets and liabilities:
Receivable from contracts with collaborators	(5,338)	0	0
Prepaid expenses and other current assets	62	(3,892)	296
Other assets	335	62	400
Operating lease liabilities	(3,386)	(2,982)	(2,721)
Accounts payable	(1,656)	3,990	(1,813)
Accrued expenses	(10,718)	(835)	(1,659)
Accrued research and development expenses	2,676	(7,847)	(579)
Accrued compensation and benefits	1,701	(3,240)	1,618
Contract liabilities	55,919	0	0
Accrued interest expense	(135)	(97)	(1)
Net cash used in operating activities	(3,468)	(159,158)	(187,032)
Cash flows from investing activities
Research and development asset acquisitions, net of cash acquired	0	0	(65)
Purchase of marketable securities	(494,777)	(441,670)	(238,060)
Maturities of marketable securities	523,800	330,700	237,500
Purchase of property and equipment	0	0	(410)
Net cash provided by (used in) investing activities	29,023	(110,970)	(1,035)
Cash flows from financing activities
Proceeds from issuance of common stock and warrants in a private offering, net of offering costs	0	201,323	119,946
Proceeds from issuance of common stock under Employee Stock Purchase Plan	629	444	1,214
Proceeds from the exercise of stock options	0	0	1,736
Proceeds from issuance of equity option pursuant to stock purchase agreement	464	0	0
Principal repayments of long-term debt	(12,581)	(11,613)	(5,806)
Net cash provided by (used in) financing activities	(11,488)	190,154	117,090
Effect of exchange rate changes on cash and cash equivalents	(102)	110	(517)
Net increase (decrease) in cash and cash equivalents	13,965	(79,864)	(71,494)
Cash and cash equivalents, at the beginning of the period	32,109	111,973	183,467
Cash and cash equivalents, at the end of the period	46,074	32,109	111,973
Supplemental disclosure of cash flow information:
Cash paid for interest	10,561	12,288	12,712
Supplemental disclosure of noncash investing and financing activities:
Right-of-use assets obtained in exchange for lease liabilities	5,298	0	3,029
Change in unrealized gain (loss) on marketable securities, net	89	191	(75)
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	$ 0	$ 0	$ 83